Allogeneic cancer cell-based immunotherapy

US9238064B2 · kind B2 · utility

Assignee

• The University of Miami · US

Inventors

• Eckhard R. Podack · Coconut Grove, US
• Joseph Rosenblatt · Hollywood, US
• Koichi Yamazaki · Sapporo, JP

Key dates

• Filing date: Jun 28, 2013
• Grant date: Jan 19, 2016
• Expiry date: Jun 28, 2033

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K2239/38
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Cell-based immunotherapy (e.g., immunization or vaccination) may be improved by frequent administration to a human subject of allogeneic cancer cells secreting a modified heat shock protein (e.g., gp96), depletion of B cells in the subject, or both. Antigen (e.g., epitope derived from neoantigen or tumor antigen of allogeneic or syngeneic cancer cells) may induce a specific immune response in the subject. For example, the epitope bound in an immunogenic complex with the secreted heat shock protein may be obtained from allogeneic cancer cells coexpressing both secreted gp96 and antigen, or from syngeneic cancer cells of the subject expressing only antigen.